Home Companies Catalysts Deep Dives
Ianalumab VAY736 PHASE3
Drug Profile
ModalityAntibody
RouteSC
Therapy AreaImmunology
Peak Sales Est$3000M
Formulations[]
Companies
NVS (ORIGINATOR)100%
Mechanism: BAFF receptor antagonist
Expert: Monoclonal antibody targeting B-cell activating factor receptor
Everyday: Targets B cells to treat autoimmune diseases
Targets: ["BAFF"]
Programs (4)
IndicationStageKey StudyRegional Status
Sjögren's diseasePHASE3NEPTUNUS-1/2[]
ITPPHASE3Phase 3[]
Lupus nephritisPHASE3Phase 3[]
SLEPHASE3Phase 3[]
Upcoming Catalysts (2)
Ianalumab - SLE - Ph3 - Topline (SIRIUS-SLE) H2 2026
Ianalumab - Sjogren's - Ph3 - Topline 2027
Notes
Anti-BAFF receptor (BAFF-R) monoclonal antibody with enhanced ADCC for autoimmune diseases including SLE and Sjögren's syndrome. Direct B-cell depletion via BAFF-R targeting offers differentiated mechanism from anti-CD20 approaches.
Data from Supabase · Updated 2026-03-24